Sacituzumab Govitecan in Metastatic Colorectal Cancer

NCT06243393 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Sacituzumab Govitecan (SG)
DRUG: Physicians Choice (PhC).

Sponsor

University Hospital Heidelberg